Comparative Pharmacology
Head-to-head clinical analysis: DRAXIMAGE DTPA versus SETHOTOPE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRAXIMAGE DTPA versus SETHOTOPE.
DRAXIMAGE DTPA vs SETHOTOPE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DRAXIMAGE DTPA (technetium Tc-99m pentetate) is a radiopharmaceutical that, after intravenous injection, distributes in the extracellular space and is cleared by glomerular filtration. It allows imaging of renal function and structure by emitting gamma radiation detectable by a gamma camera.
SETHOTOPE is a radiolabeled monoclonal antibody that binds to the prostate-specific membrane antigen (PSMA) on prostate cancer cells, delivering beta radiation (177Lu) to cause DNA damage and cell death.
Diagnostic imaging: 3-5 mCi (111-185 MBq) IV for renal studies; 10-20 mCi (370-740 MBq) IV for lung perfusion imaging.
1.0 mg IV every 12 hours for 7 days.
None Documented
None Documented
Terminal elimination half-life is approximately 1.6 hours (range 1.2-2.0 hours) in patients with normal renal function; prolonged in renal impairment (up to 50 hours in severe cases).
Terminal elimination half-life: 12 hours (range 10-14 h); clinically, dosing interval is 12-24 h to maintain therapeutic levels
Renal: 95% within 24 hours via glomerular filtration; biliary/fecal: <5%.
Renal: 70% as unchanged drug; fecal: 25% as metabolites; biliary: 5%
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical